LEVOPROPYLHEXEDRINE

Possibly Marketed Outside US

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C10H21N
Molecular Weight	155.2804
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CN[C@@H](C)CC1CCCCC1

InChI

InChIKey=JCRIVQIOJSSCQD-VIFPVBQESA-N

InChI=1S/C10H21N/c1-9(11-2)8-10-6-4-3-5-7-10/h9-11H,3-8H2,1-2H3/t9-/m0/s1

HIDE SMILES / InChI

Molecular Formula	C10H21N
Molecular Weight	155.2804
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6076581 | https://www.ncbi.nlm.nih.gov/pubmed/2874970 | https://www.ncbi.nlm.nih.gov/pubmed/13558159 | https://www.ncbi.nlm.nih.gov/pubmed/23981808http://www.ncbi.nlm.nih.gov/pubmed/13558159
Curator's Comment: description was created based on several sources, including, http://toxcenter.org/stoff-infos/l/levopropylhexedrin.pdf

Levopropylhexedrine acts similar to amphetamine, at therapeutic doses has anorexigenic effect.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Trace amine-associated receptor 1 48 Target ID: CHEMBL5857 Sources: https://www.drugbank.ca/drugs/DB06714	Agonist 2752
Adrenergic receptor alpha 65 Target ID: CHEMBL2095203 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7533806 \| https://www.ncbi.nlm.nih.gov/pubmed/21219704 \| http://www.medkoo.com/products/8742	Agonist 2752

Conditions

Condition	Modality	Highest Phase	Product
Obesity 206 Sources: https://www.ncbi.nlm.nih.gov/pubmed/13558159	Primary	Approved 8583	Eventin Approved Use Appetite depressant
Allergic rhinitis 104 Sources: https://www.drugs.com/monograph/benzedrex.html https://www.ncbi.nlm.nih.gov/pubmed/6176171	Primary	Approved 8583	Benzedrex Approved Use Self-medication for temporary relief of nasal congestion associated with the common cold, hay fever, or other allergies.
Common cold 58 Sources: https://www.drugs.com/monograph/benzedrex.html https://www.ncbi.nlm.nih.gov/pubmed/6176171	Primary	Approved 8583	Benzedrex Approved Use Self-medication for temporary relief of nasal congestion associated with the common cold, hay fever, or other allergies.
Epilepsy 121 Sources: http://www.dusunenadamdergisi.org/ing/fArticledetails.aspx?MkID=128 https://www.ncbi.nlm.nih.gov/pubmed/5719393	Primary	Approved 8583	Maliasin Approved Use Barbexoclone (Maliasin®) is an antiepileptic drug, which has been found to be effective in the treatment of epilepsy. Launch Date 1983
Obesity 206 Sources: http://www.ncbi.nlm.nih.gov/pubmed/13558159	Curative	Withdrawn	Eventin Approved Use Unknown

C_max

Value	Dose	Co-administered	Analyte	Population
1.5 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6139756/	66 mg/kg 1 times / day steady-state, oral dose: 66 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: PHENOBARBITAL	PHENOBARBITAL	PROPYLHEXEDRINE plasma	Mus musculus population: HEALTHY age: ADULT sex: MALE food status: FASTED

AUC

Value	Dose	Co-administered	Analyte	Population
1.3 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6139756/	66 mg/kg 1 times / day steady-state, oral dose: 66 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: PHENOBARBITAL	PHENOBARBITAL	PROPYLHEXEDRINE plasma	Mus musculus population: HEALTHY age: ADULT sex: MALE food status: FASTED

T_1/2

Value	Dose	Co-administered	Analyte	Population
2.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6139756/	66 mg/kg 1 times / day steady-state, oral dose: 66 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered: PHENOBARBITAL	PHENOBARBITAL	PROPYLHEXEDRINE plasma	Mus musculus population: HEALTHY age: ADULT sex: MALE food status: FASTED

Doses

Dose	Population	Adverse events
250 mg single, intravenous Abused dose Dose: 250 mg Route: intravenous Route: single Dose: 250 mg Sources: https://pubmed.ncbi.nlm.nih.gov/37732/	unknown, 17 years Health Status: unknown Age Group: 17 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/37732/	Disc. AE: Death... AEs leading to discontinuation/dose reduction: Death (grade 5) Sources: https://pubmed.ncbi.nlm.nih.gov/37732/
250 mg single, intravenous Abused dose Dose: 250 mg Route: intravenous Route: single Dose: 250 mg Sources: https://pubmed.ncbi.nlm.nih.gov/37732/	unknown, 19 years Health Status: unknown Age Group: 19 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/37732/	Disc. AE: Death... AEs leading to discontinuation/dose reduction: Death (grade 5) Sources: https://pubmed.ncbi.nlm.nih.gov/37732/
250 mg single, intravenous Abused dose Dose: 250 mg Route: intravenous Route: single Dose: 250 mg Sources: https://pubmed.ncbi.nlm.nih.gov/37732/	unknown, 19 years Health Status: unknown Age Group: 19 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/37732/	Disc. AE: Death... AEs leading to discontinuation/dose reduction: Death (grade 5) Sources: https://pubmed.ncbi.nlm.nih.gov/37732/
250 mg single, intravenous Abused dose Dose: 250 mg Route: intravenous Route: single Dose: 250 mg Sources: https://pubmed.ncbi.nlm.nih.gov/37732/	unknown, 22 years Health Status: unknown Age Group: 22 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/37732/	Disc. AE: Death, Death... AEs leading to discontinuation/dose reduction: Death (grade 5) Death (grade 5) Sources: https://pubmed.ncbi.nlm.nih.gov/37732/
250 mg single, intravenous Abused dose Dose: 250 mg Route: intravenous Route: single Dose: 250 mg Sources: https://pubmed.ncbi.nlm.nih.gov/37732/	unknown, 23 years Health Status: unknown Age Group: 23 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/37732/	Disc. AE: Death... AEs leading to discontinuation/dose reduction: Death (grade 5) Sources: https://pubmed.ncbi.nlm.nih.gov/37732/
250 mg single, intravenous Abused dose Dose: 250 mg Route: intravenous Route: single Dose: 250 mg Sources: https://pubmed.ncbi.nlm.nih.gov/37732/	unknown, 24 years Health Status: unknown Age Group: 24 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/37732/	Disc. AE: Death... AEs leading to discontinuation/dose reduction: Death (grade 5) Sources: https://pubmed.ncbi.nlm.nih.gov/37732/
250 mg single, intravenous Abused dose Dose: 250 mg Route: intravenous Route: single Dose: 250 mg Sources: https://pubmed.ncbi.nlm.nih.gov/37732/	unknown, 25 years Health Status: unknown Age Group: 25 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/37732/	Disc. AE: Death... AEs leading to discontinuation/dose reduction: Death (grade 5) Sources: https://pubmed.ncbi.nlm.nih.gov/37732/
180 mg 1 times / day steady, oral Studied dose Dose: 180 mg, 1 times / day Route: oral Route: steady Dose: 180 mg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/3709618/	healthy, 25-37 years Health Status: healthy Age Group: 25-37 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/3709618/	Sources: https://pubmed.ncbi.nlm.nih.gov/3709618/
250 mg single, intravenous Abused dose Dose: 250 mg Route: intravenous Route: single Dose: 250 mg Sources: https://pubmed.ncbi.nlm.nih.gov/37732/	unknown, 26 years Health Status: unknown Age Group: 26 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/37732/	Disc. AE: Death... AEs leading to discontinuation/dose reduction: Death (grade 5) Sources: https://pubmed.ncbi.nlm.nih.gov/37732/
250 mg single, intravenous Abused dose Dose: 250 mg Route: intravenous Route: single Dose: 250 mg Sources: https://pubmed.ncbi.nlm.nih.gov/37732/	unknown, 27 years Health Status: unknown Age Group: 27 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/37732/	Disc. AE: Death, Death... AEs leading to discontinuation/dose reduction: Death (grade 5) Death (grade 5) Sources: https://pubmed.ncbi.nlm.nih.gov/37732/
250 mg single, intravenous Abused dose Dose: 250 mg Route: intravenous Route: single Dose: 250 mg Sources: https://pubmed.ncbi.nlm.nih.gov/37732/	unknown, 28 years Health Status: unknown Age Group: 28 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/37732/	Disc. AE: Death... AEs leading to discontinuation/dose reduction: Death (grade 5) Sources: https://pubmed.ncbi.nlm.nih.gov/37732/
250 mg single, intravenous Abused dose Dose: 250 mg Route: intravenous Route: single Dose: 250 mg Sources: https://pubmed.ncbi.nlm.nih.gov/37732/	unknown, 29 years Health Status: unknown Age Group: 29 years Sex: M Sources: https://pubmed.ncbi.nlm.nih.gov/37732/	Disc. AE: Death, Death... AEs leading to discontinuation/dose reduction: Death (grade 5) Death (grade 5) Sources: https://pubmed.ncbi.nlm.nih.gov/37732/
250 mg single, intravenous Abused dose Dose: 250 mg Route: intravenous Route: single Dose: 250 mg Sources: https://pubmed.ncbi.nlm.nih.gov/37732/	unknown, 34 years Health Status: unknown Age Group: 34 years Sex: F Sources: https://pubmed.ncbi.nlm.nih.gov/37732/	Disc. AE: Death... AEs leading to discontinuation/dose reduction: Death (grade 5) Sources: https://pubmed.ncbi.nlm.nih.gov/37732/

AEs

Sourcing

Vendor/Aggregator	ID	URL
1PlusChem LLC	1P000345
ABI Chem	AC1L1P1A
AK Scientific	0377AA
Alfa Chemistry	101-40-6	https://www.alfa-chemistry.com/n-alpha-dimethylcyclohexaneethylamine-cas-101-40-6-item-289407.htm
Ambinter	Amb1098803	http://www.ambinter.com/reference/1098803
Aurum Pharmatech LLC	W-6202	http://www.Aurumpharmatech.com/Product/ProductDetails/W_6202
BioBlocks	A4312/0184095
BlocksMatrix Scientific	60201
BOC Sciences	101-40-6
Cayman Chemical	12058
ChemBridge	3001688
ChemDiv	8019-4095
Chemieliva Pharmaceutical Co., Ltd	PBCM0019750
Chemspace	CSSS00011712502	https://chem-space.com/CSSS00011712502
Compound Cloud	102541
Compound Cloud	71197
Compound Cloud	7558
eMolecules	300862979
eMolecules	36552245
eMolecules	42854733
eMolecules	981704
Enamine	BBV-34542029
Enamine	BBV-38278530
Enamine	BBV-39951695
Finetech	FT-0674106	http://www.finetechnology-ind.com/prod/detail/pub/1007-33-6.html
Fluorochem	70282
Hangzhou Yuhao Chemical Technology	RT3982
HongKong Chemhere	SCE08368
Lab Network	LN00160712
Lan Pharmatech	LQT-B08815
mcule	MCULE-7865947392	https://mcule.com/MCULE-7865947392/
MuseChem	R052098
NCI Plated 2007	170998
NCI Plated 2007	27110
Norris Pharm	NSZB-A047461
NovoSeek	7558
Princeton BioMolecular Research	OSSL_312908
Princeton BioMolecular Research	OSSL_782547
Princeton BioMolecular Research	PBMR122742
Scientific Exchange	F-394417
Smolecule	S600732	https://www.smolecule.com/products/s600732
TimTec	ST4139488	http://www.echemstore.com/st4139488-2-cyclohexyl-isopropyl-methylamine.html
Toronto Research Chemicals	C992655
Toronto Research Chemicals	P837150
Vitas-M Laboratory	STK664138
Wonderchem	WD04JUW
Zelinsky Institute	UZI/2661800
ZINC	ZINC000001481910	http://zinc15.docking.org/substances/ZINC000001481910
ZINC	ZINC000001482094	http://zinc15.docking.org/substances/ZINC000001482094

PubMed

Title	Date	PubMed
Propylhexdrine.	1986-06	2874970
Intravenous prophylhexedrine (Benzedrex®) abuse and sudden death.	1979-07	37732
Intravenous abuse of propylhexedrine.	1977-01	45496
[L-thyroxine propylhexedrine in the treatment of obesity. Crossed double blind study].	1974-05-01	4612507
A comparison of the anticonvulsant properties of l-propylhexedrine, phenobarbital and a salt-like complex of l-propylhexedrine and phenobarbital in mice and rats.	1967-12	6076581
[Therapeutic experiences with the appetite depressant eventin].	1958-04-05	13558159

Patents

Sample Use Guides

In Vivo Use Guide

Intranasal AdministrationAdminister topically to the nasal mucosa as an inhalation.Avoid contamination of the inhaler tip; inhaler is for single-patient use only.Warm drug container in the hands prior to use to increase drug volatility.Inhale vapor through each nostril while head is erect; blow nose thoroughly after 3–5 minutes. The Benzedrex propylhexedrine inhaler delivers 0.4–0.5 mg of the drug in each 800 mL of air. AdultsNasal CongestionIntranasal2 inhalations (0.4–0.5 mg) in each nostril no more than every 2 hours.

Route of Administration: Nasal

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:18:59 GMT 2025` Edited by `admin` on `Mon Mar 31 18:18:59 GMT 2025`
Record UNII	4R3L4TYV09
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

LEVOPROPYLHEXEDRINE

Official Name

English

EVENTIN

Preferred Name

English

levopropylhexedrine [INN]

Common Name

English

L-PROPYLHEXEDRINE

Common Name

English

L-1-CYCLOHEXYL-2-METHYLAMINOPROPANE

Common Name

English

Levopropylhexedrine [WHO-DD]

Common Name

English

PROPYLHEXEDRINE L-FORM [MI]

Common Name

English

(-)-N,.ALPHA.-DIMETHYLCYCLOHEXANEETHYLAMINE

Systematic Name

English

PROPYLHEXEDRINE, (S)-

Common Name

English

(-)-PROPYLHEXEDRINE

Common Name

English

CYCLOHEXANEETHANAMINE, N,.ALPHA.-DIMETHYL-, (.ALPHA.S)-

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C29709